Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 5/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.44 |
| ▸ | METAP2 | P50579 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23884385 | 0.79 | HSP90AA1 (0.47) | CHEK1MKNK1NOS1DYRK1AMETAP2 | |
| SCHEMBL31460000 | 0.79 | PIM1 (0.50) | CHEK1NOS1DYRK1AMETAP2KDM4E | |
| Hydrochloric Acid SCHEMBL11207451 | 0.77 | PIM1 (0.49) | CHEK1NOS1DYRK1AMETAP2KDM4E | |
| SCHEMBL10771547 | 0.75 | CHEK1 (0.53) | CHEK1MKNK1NOS1DYRK1AMETAP2 | |
| SCHEMBL6616315 | 0.74 | CYP1A2 (0.46) | DYRK1AMETAP2KDM4EMAPTKMT2A | |
| SCHEMBL6617020 | 0.74 | CYP1A2 (0.46) | DYRK1AMETAP2KDM4EMAPTKMT2A | |
| SCHEMBL3623976 | 0.74 | MKNK1 (0.58) | CHEK1MKNK1NOS1DYRK1AMETAP2 | |
| SCHEMBL5129566 | 0.74 | MKNK1 (0.63) | CHEK1MKNK1NOS1DYRK1AMETAP2 | |
| SCHEMBL6616738 | 0.73 | SMN1; SMN2 (0.58) | DYRK1AMAPTCSNK2A1ROCK2ALDH1A1 | |
| SCHEMBL14425572 | 0.72 | CHEK1 (0.46) | CHEK1MKNK1NOS1DYRK1AMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200163877-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC. | 2020-05-28 | — | — | US | claimed |
| US-20190321467-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC. | 2019-10-24 | — | — | US | claimed |
| US-20150224055-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC | 2015-08-13 | — | — | US | claimed |
| US-11712419-B2 | Liposome formulations | OPKO PHARMACEUTICALS, LLC (US) | 2023-08-01 | — | — | US | disclosed |
| US-11458199-B2 | Liposome formulations | OPKO PHARMACEUTICALS, LLC (US) | 2022-10-04 | — | — | US | disclosed |
| EP-2887958-B1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS LLC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20200163877-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC. | 2020-05-28 | — | — | US | disclosed |
| US-10548841-B2 | Liposome formulations | OPKO PHARMACEUTICALS, LLC (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190321467-A1 | LIPOSOME FORMULATIONS | OPKO PHARMACEUTICALS, LLC. | 2019-10-24 | — | — | US | disclosed |
| EP-3165606-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | Ophthotech Corporation (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20160264969-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | OPHTHOTECH CORPORATION | 2016-09-15 | — | — | US | disclosed |
| EP-0779889-A4 | PYRAZOLO 3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE | RHONE POULENC RORER PHARMA (US) | 2000-02-23 | — | — | EP | disclosed |
| EP-0779889-A4 | PYRAZOLO 3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE | RHONE POULENC RORER PHARMA (US) | 2000-02-23 | — | — | EP | disclosed |
| EP-0779889-A1 | PYRAZOLO 3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1997-06-25 | — | — | EP | disclosed |
| EP-0779889-A1 | PYRAZOLO 3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1997-06-25 | — | — | EP | disclosed |
| WO-1996007658-A1 | PYRAZOLO[3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-03-14 | — | — | WO | disclosed |
| WO-1996007658-A1 | PYRAZOLO[3,4-g]QUINOXALINE COMPOUNDS WHICH INHIBIT PDGF RECEPTOR PROTEIN TYROSINE KINASE | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-03-14 | — | — | WO | disclosed |
| US-5476851-A | Administering as therapeutic agents for various disease states which are characterized by uncontrolled cellular proliferation | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1995-12-19 | — | — | US | disclosed |
| US-5476851-A | Administering as therapeutic agents for various disease states which are characterized by uncontrolled cellular proliferation | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1995-12-19 | — | — | US | disclosed |
| US-5476851-A | Administering as therapeutic agents for various disease states which are characterized by uncontrolled cellular proliferation | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1995-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264969-A1 | METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES | VEGFA, PDGFA, PGF | CHEK1 4323/4885MKNK1 4136/4885NOS1 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.